TY - JOUR
T1 - Renal osteodystrophy
AU - Hruska, Keith A.
AU - Teitelbaum, Steven L.
PY - 1995/7/20
Y1 - 1995/7/20
N2 - Renal osteodystrophy, the term used to describe the skeletal complications of end-stage renal disease, is a multifactorial disorder of bone remodeling. The actions of some of the factors involved are well defined, and successful strategies have been designed to prevent them. For example, the identification of secondary hyperparathyroidism and 1α,25-dihydroxycholecalciferol (1α,25-dihydroxyvitamin D3) deficiency as major contributors to renal osteodystrophy has led to the development of treatment regimens that can maintain normal serum calcium and phosphate concentrations, reduce parathyroid hormone secretion, and correct a deficiency of 1α,25-dihydroxycholecalciferol. These improvements in treatment have resulted in decreases in the frequency and. . .
AB - Renal osteodystrophy, the term used to describe the skeletal complications of end-stage renal disease, is a multifactorial disorder of bone remodeling. The actions of some of the factors involved are well defined, and successful strategies have been designed to prevent them. For example, the identification of secondary hyperparathyroidism and 1α,25-dihydroxycholecalciferol (1α,25-dihydroxyvitamin D3) deficiency as major contributors to renal osteodystrophy has led to the development of treatment regimens that can maintain normal serum calcium and phosphate concentrations, reduce parathyroid hormone secretion, and correct a deficiency of 1α,25-dihydroxycholecalciferol. These improvements in treatment have resulted in decreases in the frequency and. . .
UR - http://www.scopus.com/inward/record.url?scp=0029649011&partnerID=8YFLogxK
M3 - Review article
C2 - 7791820
AN - SCOPUS:0029649011
SN - 0028-4793
VL - 333
SP - 166
EP - 174
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 3
ER -